Continuous vs intermittent induction of labor with oxytocin in nulliparous patients: a randomized controlled trial

What Was Tested

Researchers studied Oxytocin in this randomized controlled trial publication.

Oxytocin is considered the drug of choice for the induction of labor, although the optimal protocol and infusion duration remain to be determined.

Who Took Part

PubMed tags the participants as women only.

Nulliparous patients with a singleton pregnancy at a vertex presentation and a Bishop score ≥6 were randomly assigned to receive either continuous (16 hours, with a 4 hours pause in between infusions) or intermittent (8 hours, with a 4 hours pause in between infusions) oxytocin infusion, until delivery.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Oxytocin and who got the comparison, which limits bias.

A randomized controlled trial was performed at a single tertiary medical center, between January 1, 2020 and June 30, 2022.

In both groups, infusion was halted when signs of maternal or fetal compromise were observed.

Randomization was conducted with a computer randomization sequence generation program.

The primary outcome was delivery within 24 hours from the first oxytocin infusion and the secondary outcome included time-to-delivery, mode of delivery, and additional maternal and neonatal outcomes.

What Was Measured

Topics PubMed links to this paper include Oxytocin, Oxytocics, Chorioamnionitis, Cervical Ripening and Labor, Induced.

The authors tagged it with the keywords induction of labor and nulliparity.

What This Means in Plain Language

The paper is a randomized study of Oxytocin.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (American journal of obstetrics & gynecology MFM), a journal based in United States.

More context: the Oxytocin compound page, all human trials.